Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Human Genome says cancer drug is safe
“Preclinical studies have shown that adding HGS-ETR1 to gemcitabine and cisplatin results in increased cytotoxicity. These data warrant further study of HGS-ETR1 in combination with chemotherapeutic agents in
“Preclinical studies have shown that adding HGS-ETR1 to gemcitabine and cisplatin results in increased cytotoxicity. These data warrant further study of HGS-ETR1 in combination with chemotherapeutic agents in
The news comes as Merck has other liability concerns relating to the drug Vioxx, which was withdrawn from the market after it was suggested that the treatment could
Biovitrum’s assignment is to develop the existing process for the biotechnical manufacturing of RES 08 to a standard that meets the demands of a clinical phase III trial,
The purpose of this study was to gather more information about the safety of Aczone, a prescription topical medicine, in treating patients with acne who have certain blood
The subcontract was made under a deal between SRI International in California, and the National Institute of Allergy and Infectious Diseases (NIAID). SRI International was awarded a $56.9
The agreement includes the payment of an upfront fee to Bioject, payments to extend the option term and license additional targets, payments upon the achievement of specific milestones,
“Mifamurtide, when added to combination chemotherapy in this large phase III trial, provided a significant benefit on disease free survival and on overall survival of young osteosarcoma patients.
The identification of this protein, called interleukin-23 (IL-23), is an important finding that gives researchers a specific target for developing new therapies that could potentially prolong the life
IPI-504, Infinity's lead oncology drug candidate, is a small molecule inhibitor of Heat Shock Protein 90 (Hsp90) that is being jointly developed by Infinity and MedImmune for the
The Data and Safety Monitoring Board (DSMB) reviewed mortality and other safety data from the first 21 patients enrolled in the trial at Johannesburg Hospital Trauma Unit in